New Age Alpha Funds Trust is set to reorganize its NAA Allocation Fund into a newly created exchange-traded fund (ETF), the NAA Allocation ETF. This significant move, approved by the Board of Trustees, aims to streamline operations and offer shareholders a more efficient investment vehicle.
The reorganization is scheduled to occur on December 4, 2026. By transitioning from a conventional open-end mutual fund to an ETF structure, the NAA Allocation ETF is expected to provide benefits such as lower net annual operating expenses and the ability to trade shares throughout the day on a national securities exchange.
Background
New Age Alpha Funds Trust, based in Rye, New York, is an investment company that offers various funds to investors. The NAA Allocation Fund, which is undergoing this reorganization, has been a part of the Trust's offerings. Recent filings indicate that the Trust has been active in updating its fund structures to better serve its investors.
What the Filing Says
The recent filing states, "New Age Alpha Advisors, LLC... has recommended, and the Board has approved, the reorganization of the Target Fund into the NAA Allocation ETF." This indicates a clear strategy to enhance shareholder value through operational efficiency and cost reduction.
Impact
This reorganization may significantly affect shareholders of the NAA Allocation Fund, as they will need to ensure that they hold their shares through a brokerage account capable of accepting ETF shares. Those who do not may face liquidation of their shares and receive a cash distribution, which could have tax implications.
What's Next
The filing does not say what happens next, but shareholders are encouraged to review the enclosed Information Statement/Prospectus carefully for further details on the reorganization process.
Read Next
Supernus Pharmaceuticals CFO Receives Restricted Stock Units
CEO of Bloomingdale's Reports Stock Transactions in SEC Filing
Bertolini Jeffrey Reports Insider Transactions for Carlsmed, Inc.
Vessey Rupert Acquires 2,750 Shares in Bio-Techne Corp
Supernus Pharmaceuticals CMO acquires 70,000 stock units
Bausch & Lomb director acquires 1,256 shares in filing







